Kuur Therapeutics   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2005)
Status: Acquired by Athenex, Inc. (2021)

Organization Overview

First Clinical Trial
2008
NCT01077908
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cell Medica, Inc | Cell Medica Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

cmv-specific t-cells (2 trials)

Drugs in Phase 2 Trials (3)

Key: Kuur Therapeutics (2) Acquired (1)

adenovirus-specific t-cells (1 trial)

cmd-003 (2 trials)

dlx105 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenoviridae Infections (Phase 2)

Cytomegalovirus Infections (Phase 3)

Lymphoma (Phase 2)

Lymphoma, Extranodal NK-T-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoproliferative Disorders (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 8
  • # of Trial APIs: 4